List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7527649/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Structure of the mouse behaviour on the elevated plus-maze test of anxiety. Behavioural Brain Research, 1997, 86, 105-112.	2.2	149
2	Expression and Function of CB1 Receptor in the Rat Striatum: Localization and Effects on D1 and D2 Dopamine Receptor-Mediated Motor Behaviors. Neuropsychopharmacology, 2008, 33, 1667-1679.	5.4	135
3	Structure of the rat's behaviour in the hot plate test. Behavioural Brain Research, 1993, 56, 171-176.	2.2	130
4	Cellular and Functional Recovery of Parkinsonian Rats after Intrastriatal Transplantation of Carotid Body Cell Aggregates. Neuron, 1998, 20, 197-206.	8.1	123
5	Role of cannabis and endocannabinoids in the genesis of schizophrenia. Psychopharmacology, 2009, 206, 531-549.	3.1	123
6	Effects of weekly or daily exposure to the elevated plus-maze in male mice. Behavioural Brain Research, 1997, 87, 233-238.	2.2	114
7	Opiate anti-nociception is attenuated following lesion of large dopamine neurons of the periaqueductal grey: critical role for D1 (not D2) dopamine receptors. Pain, 2004, 110, 205-214.	4.2	95
8	Selective dopamine depletion within the medial prefrontal cortex induces anxiogenic-like effects in rats placed on the elevated plus maze. Brain Research, 1997, 762, 281-284.	2.2	93
9	Cannabinoid CB1 antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental parkinsonism. Neurobiology of Disease, 2005, 18, 591-601.	4.4	92
10	Prefrontocortical Dopamine Loss in Rats Delays Long-Term Extinction of Contextual Conditioned Fear, and Reduces Social Interaction Without Affecting Short-Term Social Interaction Memory. Neuropsychopharmacology, 2003, 28, 490-498.	5.4	88
11	Behavioral sensitization to cocaine after a brief social defeat stress: c-fos expression in the PAG. Psychopharmacology, 1999, 141, 225-234.	3.1	82
12	Pathogenesis of Parkinson's Disease: Prospects of Neuroprotective and Restorative Therapies. Molecular Neurobiology, 2004, 29, 15-30.	4.0	80
13	Prefrontocortical dopamine depletion induces antidepressant-like effects in rats and alters the profile of desipramine during Porsolt's test. Neuroscience, 1999, 88, 609-615.	2.3	75
14	Experimental Parkinsonism Alters Anandamide Precursor Synthesis, and Functional Deficits are Improved by AM404: A Modulator of Endocannabinoid Function. Neuropsychopharmacology, 2004, 29, 1134-1142.	5.4	67
15	Oleoylethanolamide exerts partial and dose-dependent neuroprotection of substantia nigra dopamine neurons. Neuropharmacology, 2009, 56, 653-664.	4.1	63
16	Role for Dopamine Neurons of the Rostral Linear Nucleus and Periaqueductal Gray in the Rewarding and Sensitizing Properties of Heroin. Neuropsychopharmacology, 2006, 31, 1475-1488.	5.4	51
17	Antagonism of peripheral 5-HT4 receptors reduces visceral and cutaneous pain in mice, and induces visceral analgesia after simultaneous inactivation of 5-HT3 receptors. Brain Research, 1998, 788, 20-24.	2.2	49
18	Effects of morphine and naloxone on behaviour in the hot plate test: an ethopharmacological study in the rat. Psychopharmacology, 1994, 113, 500-510.	3.1	46

#	Article	IF	CITATIONS
19	Functional Regeneration in a Rat Parkinson's Model after Intrastriatal Grafts of Glial Cell Line-Derived Neurotrophic Factor and Transforming Growth Factor β1-Expressing Extra-Adrenal Chromaffin Cells of the Zuckerkandl's Organ. Journal of Neuroscience, 2001, 21, 9888-9895.	3.6	44
20	Effects on turning of microinjections into basal ganglia of D1 and D2 dopamine receptors agonists and the cannabinoid CB1 antagonist SR141716A in a rat Parkinson's model. Neurobiology of Disease, 2004, 16, 377-385.	4.4	43
21	Effects of the endogenous PPARâ€Î± agonist, oleoylethanolamide on MDMAâ€induced cognitive deficits in mice. Synapse, 2010, 64, 379-389.	1.2	42
22	May the Evaluation of Nitrosative Stress Through Selective Increase of 3-Nitrotyrosine Proteins Other Than Nitroalbumin and Dominant Tyrosine-125/136 Nitrosylation of Serum α-Synuclein Serve for Diagnosis of Sporadic Parkinson's Disease?. Antioxidants and Redox Signaling, 2013, 19, 912-918.	5.4	38
23	The systemic administration of oleoylethanolamide exerts neuroprotection of the nigrostriatal system in experimental Parkinsonism. International Journal of Neuropsychopharmacology, 2014, 17, 455-468.	2.1	37
24	Oleoylethanolamide doseâ€dependently attenuates cocaineâ€induced behaviours through a <scp>PPARα</scp> receptorâ€independent mechanism. Addiction Biology, 2013, 18, 78-87.	2.6	36
25	Ethopharmacological analysis of naloxone-precipitated morphine withdrawal syndrome in rats: a newly-developed "etho-score― Psychopharmacology, 1995, 122, 122-130.	3.1	34
26	Cells of the sympathoadrenal lineage: Biological properties as donor tissue for cell-replacement therapies for Parkinson's disease. Brain Research Reviews, 2005, 49, 343-354.	9.0	31
27	May Serum Levels of Advanced Oxidized Protein Products Serve as a Prognostic Marker of Disease Duration in Patients with Idiopathic Parkinson's Disease?. Antioxidants and Redox Signaling, 2013, 18, 1296-1302.	5.4	30
28	Differential effects of weekly and daily exposure to the hot plate on the rat's behavior. Physiology and Behavior, 1994, 55, 1157-1162.	2.1	29
29	Cannabinoid CB1 receptor antagonism markedly increases dopamine receptor-mediated stereotypies. European Journal of Pharmacology, 2007, 559, 180-183.	3.5	28
30	Response to Methadone Maintenance Treatment is Associated with the MYOCD and GRM6 Genes. Molecular Diagnosis and Therapy, 2010, 14, 171-178.	3.8	28
31	QF2004B, a potential antipsychotic butyrophenone derivative with similar pharmacological properties to clozapine. Neuropharmacology, 2006, 51, 251-262.	4.1	26
32	Antiparkinsonian trophic action of glial cell line-derived neurotrophic factor and transforming growth factor β1 is enhanced after co-infusion in rats. Experimental Neurology, 2010, 226, 136-147.	4.1	26
33	The transient receptor potential vanilloid-1 is localized at excitatory synapses in the mouse dentate gyrus. Brain Structure and Function, 2015, 220, 1187-1194.	2.3	26
34	Behavioral Expression of Opiate Withdrawal is Altered after Prefrontocortical Dopamine Depletion in Rats Monoaminergic Correlates. Neuropsychopharmacology, 2001, 25, 204-212.	5.4	22
35	Adrenergic Hyperactivity and Metanephrine Excess in the Nucleus Accumbens After Prefrontocortical Dopamine Depletion. Journal of Neurophysiology, 2001, 85, 1270-1274.	1.8	21
36	Sensorimotor gating in mice is disrupted after AM404, an anandamide reuptake and degradation inhibitor. Psychopharmacology, 2004, 175, 220-4.	3.1	19

#	Article	IF	CITATIONS
37	Ethological analysis of the male rat's socioagonistic behavior in a resident-intruder paradigm. Aggressive Behavior, 1990, 16, 41-55.	2.4	18
38	Dorsal and median raphe serotonergic system lesion does not alter the opiate withdrawal syndrome. Pharmacology Biochemistry and Behavior, 2002, 72, 979-986.	2.9	18
39	Intra-accumbens rimonabant is rewarding but induces aversion to cocaine in cocaine-treated rats, as does in vivo accumbal cannabinoid CB1 receptor silencing: critical role for glutamate receptors. Neuroscience, 2010, 167, 205-215.	2.3	17
40	Alteration of neuropathic and visceral pain in female C57BL/6J mice lacking the PPAR-α gene. Psychopharmacology, 2012, 222, 477-488.	3.1	17
41	Inhibition of 5-HT Neurotransmission Increases Clonidine Protective Effects on Naloxone-induced Conditioned Place Aversion in Morphine-dependent Rats. Neuropsychopharmacology, 2003, 28, 276-283.	5.4	16
42	The absence of a functional peroxisome proliferator-activated receptor-alpha gene in mice enhances motor sensitizing effects of morphine, but not cocaine. Neuroscience, 2009, 164, 667-675.	2.3	16
43	Palmitoylethanolamide prevents neuroinflammation, reduces astrogliosis and preserves recognition and spatial memory following induction of neonatal anoxia-ischemia. Psychopharmacology, 2018, 235, 2929-2945.	3.1	16
44	May the Thyroid Gland and Thyroperoxidase Participate in Nitrosylation of Serum Proteins and Sporadic Parkinson's Disease?. Antioxidants and Redox Signaling, 2014, 21, 2143-2148.	5.4	15
45	Acute Δ-tetrahydrocannabinol exposure facilitates quinpirole-induced hyperlocomotion. Pharmacology Biochemistry and Behavior, 2005, 81, 71-77.	2.9	14
46	Grafts of extra-adrenal chromaffin cells as aggregates show better survival rate and regenerative effects on parkinsonian rats than dispersed cell grafts. Neurobiology of Disease, 2008, 29, 529-542.	4.4	14
47	Analysis of neurotrophic and antioxidant factors related to midbrain dopamine neuronal loss and brain inflammation in the cerebrospinal fluid of the elderly. Experimental Gerontology, 2018, 110, 54-60.	2.8	14
48	Changes in dopaminergic neurotransmission do not alter somatic or motivational opiate withdrawal-induced symptoms in rats Behavioral Neuroscience, 2003, 117, 995-1005.	1.2	13
49	Effects of acute and repeated cocaine on markers for neural plasticity within the mesolimbic system in rats. Psychopharmacology, 2015, 232, 57-62.	3.1	13
50	Role for D-Serine within the Ventral Tegmental Area in the Development of Cocaine's Sensitization. Neuropsychopharmacology, 2008, 33, 995-1003.	5.4	12
51	Native α-Synuclein, 3-Nitrotyrosine Proteins, and Patterns of Nitro-α-Synuclein-Immunoreactive Inclusions in Saliva and Submandibulary Gland in Parkinson's Disease. Antioxidants, 2021, 10, 715.	5.1	12
52	Psychostimulant Drugs and Neuroplasticity. Pharmaceuticals, 2011, 4, 976-991.	3.8	11
53	Oleoylethanolamide and Palmitoylethanolamide Protect Cultured Cortical Neurons Against Hypoxia. Cannabis and Cannabinoid Research, 2018, 3, 171-178.	2.9	11
54	Mice lacking the peroxisome proliferator-activated receptor alpha gene present reduced number of dopamine neurons in the substantia nigra without altering motor behavior or dopamine neuron decline over life. Neuroscience, 2011, 186, 161-169.	2.3	10

#	Article	IF	CITATIONS
55	Excess amounts of 3-iodo-l-tyrosine induce Parkinson-like features in experimental approaches of Parkinsonism. NeuroToxicology, 2018, 67, 178-189.	3.0	10
56	Fibroblast growth factor-1 within the ventral tegmental area participates in motor sensitizing effects of morphine. Neuroscience, 2010, 165, 198-211.	2.3	9
57	Behavioral study in rats of paired accumbens-lesioned residents and intact intruders. Physiology and Behavior, 1990, 47, 941-947.	2.1	8
58	Single restraint stress sensitizes acute chewing movements induced by haloperidol, but not if the 5-HT1A agonist 8-OH-DPAT is given prior to stress. Brain Research, 1997, 755, 351-355.	2.2	8
59	Sensitization to cocaine is inhibited after intra-accumbal GR103691 or rimonabant, but it is enhanced after co-infusion indicating functional interaction between accumbens D3 and CB1 receptors. Psychopharmacology, 2011, 214, 949-959.	3.1	8
60	Cerebrospinal fluid lactoperoxidase level is enhanced in idiopathic Parkinson's disease, and correlates with levodopa equivalent daily dose. Brain Research, 2021, 1761, 147411.	2.2	8
61	ATP13A2 levels in serum and cerebrospinal fluid in patients with idiopathic Parkinson's disease. Parkinsonism and Related Disorders, 2021, 88, 3-9.	2.2	6
62	Myeloperoxidase and Advanced Oxidation Protein Products in the Cerebrospinal Fluid in Women and Men with Parkinson's Disease. Antioxidants, 2022, 11, 1088.	5.1	6
63	A Rare Paronychia with Superinfection with Prevotella bivia and Staphylococcus haemolyticus: The Importance of Early Microbiological Diagnosis. Pathogens, 2020, 9, 999.	2.8	5
64	Morphophysiology of the Zuckerkandl's paraganglion: Effects of dexamethasone and aging. Neurobiology of Aging, 2010, 31, 2115-2127.	3.1	4
65	La plasticidad sináptica mediada por endocannabinoides y «trastornos por consumo de drogas». NeurologÃa, 2019, , .	0.7	2
66	A Cross-Sectional Study of Foot Growth and Its Correlation with Anthropometric Parameters in a Representative Cohort of Schoolchildren from Southern Spain. International Journal of Environmental Research and Public Health, 2021, 18, 4031.	2.6	2
67	¿Presenta la enfermedad de Parkinson una haloenzimopatÃa?. NeurologÃa, 2022, 37, 661-667.	0.7	1
68	Pathogenesis of Oxidative Stress and the Destructive Cycle in the Substantia Nigra in Parkinson's Disease. , 2009, , 1-11.		1
69	Cell-Based Replacement Therapies for Parkinson's Disease. , 2009, , 1-27.		0